Cancer
Cutaneous Melanoma
CI-CAN-00000795CMExplore in graph →
Top-level78 active trials1 approved drugs60 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000795CMExplore in graph →
Clinical trials
241 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01511913 | A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma(IMAGE) | completed | — | 1,411 | Bristol-Myers SquibbINDUSTRY | 15 | Dec 28, 2021 |
| clinicaltrials |
| NCT02716948 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03663647 | Advanced Melanoma in Russian Experience(ADMIRE) | completed | — | 382 | MelanomaPRO, RussiaOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT03112668 | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners | completed | N/A | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04789421 | Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management(NET-DAM) | completed | N/A | 3,248 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 0 | Mar 9, 2021 | clinicaltrials |
| NCT01886235 | Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery | completed | N/A | 10 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04274816 | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | completed | Phase 1 | 13 | A.J.M. van den EertweghOTHER | 0 | Feb 18, 2020 | clinicaltrials |
| NCT02320305 | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | completed | Early Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03628417 | Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases | completed | N/A | 7 | Szeged UniversityOTHER | 0 | Jan 2, 2020 | clinicaltrials |
| NCT01196416 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01789827 | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy | completed | Early Phase 1 | 5 | Mayo ClinicOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01258855 | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | May 10, 2019 | clinicaltrials |
| NCT02668887 | Employment and Quality of Life in Patients With Malignant Melanoma | completed | — | 221 | Fachklinik Hornheide an der Universität MünsterOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT01460875 | Recombinant Interferon Alfa-2b in Treating Patients With Melanoma | completed | N/A | 34 | William CarsonOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT03541148 | Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma | completed | Phase 2 | 20 | Catalysis SLINDUSTRY | 1 | May 30, 2018 | clinicaltrials |
| NCT00387751 | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00019682 | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma | completed | Phase 3 | 185 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT00397982 | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma(Mel47) | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01395121 | A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread(NICAM) | completed | Phase 2 | 29 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01477463 | Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers | completed | N/A | 24 | Stanford UniversityOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00424515 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma(BUS255) | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00577382 | SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | completed | Phase 2 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01665183 | Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 2 | Feb 25, 2016 | clinicaltrials |
| NCT02417948 | Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans | completed | N/A | 143 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00110019 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 3 | 823 | National Cancer Institute (NCI)NIH | 2 | Oct 19, 2015 | clinicaltrials |
| NCT00866177 | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 167 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2015 | clinicaltrials |
| NCT01960634 | Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma(BRAFV600) | completed | — | 58 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT01989559 | Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00470470 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01444560 | miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi | completed | — | 21 | Ruhr University of BochumOTHER | 1 | Oct 16, 2012 | clinicaltrials |
| NCT00615095 | Differential Risks for Melanoma: p16 and DNA Repair | completed | — | 323 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 20, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Apr 19, 2022source: clinicaltrials